Skip to content
Chlorzoxazone
Paraflex, Parafon, Strifon (chlorzoxazone) is a small molecule pharmaceutical. Chlorzoxazone was first approved as Paraflex on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, myositis, pain, and spasm in the USA. It is known to target intermediate conductance calcium-activated potassium channel protein 4 and small conductance calcium-activated potassium channel protein 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorzoxazone
Tradename
Company
Number
Date
Products
PARAFON FORTE DSCJohnson & JohnsonN-011529 DISCN1987-06-15
1 products, RLD
PARAFLEXJohnson & JohnsonN-011300 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
chlorzoxazoneANDA2023-06-09
parafon dscANDA2010-02-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
muscle crampHP_0003394D009120—
muscle rigidityHP_0002063D009127—
myositisEFO_0000783D009220G72.49
painEFO_0003843D010146R52
spasm—D013035M62.83
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BB: Oxazol, thiazine, and triazine derivatives centrally acting muscle relaxants
— M03BB03: Chlorzoxazone
— M03BB53: Chlorzoxazone, combinations excl. psycholeptics
— M03BB73: Chlorzoxazone, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10451713644
Essential hypertensionD000075222I10——5117
Chronic renal insufficiencyD051436N18—2—3—5
Left ventricular hypertrophyD017379EFO_0003896———2—2
Heart failureD006333EFO_0003144I50——11—2
Cardio-renal syndromeD059347—1—1—2
Aortic valve stenosisD001024EFO_0000266Q25.1———1—1
Aortic valve insufficiencyD001022EFO_0007148———1—1
Metabolic syndromeD024821EFO_0000195E88.81———1—1
OverweightD050177E66.3———1—1
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I98—27—110
Heart diseasesD006331EFO_0003777I51.9—25—18
Healthy volunteers/patients—2—1——3
Vascular diseasesD014652EFO_0004264I77—21——3
Myocardial infarctionD009203EFO_0000612I21——1—12
Coronary diseaseD003327——1—12
Sleep apnea syndromesD012891EFO_0003877G47.3——1——1
Kidney transplantationD016030——1——1
HypercholesterolemiaD006937HP_0003124——1——1
Diabetes mellitusD003920EFO_0000400E08-E13——1——1
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10—1———1
HypercalciuriaD053565R82.994—1———1
Renal insufficiencyD051437HP_0000083N19—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ambulatory blood pressure monitoringD018660————11
Vascular stiffnessD059289————11
Kidney calculiD007669EFO_0004253N20.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCHLORZOXAZONE
INNchlorzoxazone
Description
Chlorzoxazone is a member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm. It has a role as a muscle relaxant and a sedative. It is a member of 1,3-benzoxazoles, an organochlorine compound and a heteroaryl hydroxy compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=c1[nH]c2cc(Cl)ccc2o1
Identifiers
PDB1M8D
CAS-ID95-25-0
RxCUI2410
ChEMBL IDCHEMBL1371
ChEBI ID3655
PubChem CID2733
DrugBankDB00356
UNII IDH0DE420U8G (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNN4
KCNN4
KCNN2
KCNN2
Organism
Homo sapiens
Gene name
KCNN4
Gene synonyms
IK1, IKCA1, KCA4, SK4
NCBI Gene ID
3783
Protein name
intermediate conductance calcium-activated potassium channel protein 4
Protein synonyms
IK1, IKCa1, intermediate-conductance Ca2+-activated K+ channel, KCa3.1, KCa3.1, KCa4, potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4, potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4, putative erythrocyte intermediate conductance calcium-activated potassium Gardos channel, Putative Gardos channel, SKCa 4, SKCa4, small conductance calcium-activated potassium channel 4
Uniprot ID
Q53XR4
Mouse ortholog
Kcnn4 (16534)
intermediate conductance calcium-activated potassium channel protein 4 (Q9CY39)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,377 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,843 adverse events reported
View more details